News
Medical Device Network on MSN6d
Abbott’s studies show CGM technology linked to lower heart hospitalisation riskAbbott's REFLECT real-world retrospective studies indicate that FreeStyle Libre continuous glucose monitoring (CGM) ...
Abbott’s FreeStyle Libre continuous glucose monitoring technology is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes, according ...
Abbott Laboratories (NYSE:ABT) recently shared findings from its REFLECT real-world studies, revealing that the use of its FreeStyle Libre® continuous glucose monitoring (CGM) system is linked to ...
Abbott today announced results from real-world studies demonstrating benefits with its FreeStyle Libre CGM technology.
(RTTNews) - Abbott Laboratories (ABT) Thursday announced positive data from REFLECT studies of its FreeStyle Libre continuous glucose monitoring (CGM) technology. The REFLECT studies, funded by ...
A pair of studies published in Diabetologia demonstrate that use of continuous glucose monitors (CGMs) reduces ...
Abbott announced results from its REFLECT real-world studies that show the use of FreeStyle Libre continuous glucose monitoring (CGM) technology is associated with a significant reduction in the risk ...
They let you keep track of your blood sugar levels in a less invasive way. One type of CGM is Abbott’s Freestyle Libre. Medicare took some time to accept these devices. However, for the last few ...
April 29, 2025 /PRNewswire/ -- Abbott (ABT), the global leader in continuous glucose monitoring (CGM ... with the outside US version of the FreeStyle Libre 14 day system. Data is applicable ...
Abbott Laboratories (NYSE:ABT) recently shared findings from its REFLECT real-world studies, revealing that the use of its FreeStyle Libre® continuous glucose monitoring (CGM) system is linked to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback